On September 9, 2020, Recursion Pharmaceuticals, Inc. closed the transaction. The company received $239,000,000 in the transaction led by new investor Leaps by Bayer for $50,000,000. The transaction also included participation from new investors Casdin Capital, LLC, Catalio Capital Management, LP, Laurion Capital Management LP, Samsara Biocapital, L.P. a fund managed by Samsara BioCapital LLC, returning investors Baillie Gifford & Co Limited, Mubadala Ventures, Data Collective, Lux Capital Management, Obvious Ventures, L.P., Felicis Ventures, EPIC Ventures, Two Sigma Ventures, LP, Advantage Capital Partners, Intermountain Ventures and other new and existing investors. The round was over-subscribed. The company raised $235,506,731 from 38 investors pursuant to exemption provided under Regulation D.